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Abstract. The most commonly used biomarkers to
predict the response of breast cancer patients to ther-
apy are oestrogen receptor (ER), progesterone receptor
(PgR), and human epidermal growth factor receptor
2 (HER2). Patients positive for these biomarkers are
eligible for specific therapies such as anti-oestrogen
therapy in the event of ER and PgR positivity, and
trastuzumab, a monoclonal antibody, in the case of
HER2 positive patients. Patients who are negative for
all these three biomarkers, the so-called triple negatives,
however, derive little benefit from such therapies. The
PI3K/Akt pathway is activated in triple negative breast
cancer cases, providing a possible target for therapy.
The activation of Akt was investigated in Maltese
triple negative breast cancer cases using an antibody
detecting Akt phosphorylated at serine 473 (anti-Akt
pS473). The study showed that 26% of triple negative
breast cancer patients had an elevated level of Akt
(pS473). Furthermore, FTY720, a pharmacological
activator of the phosphatase PP2A, was shown to block
Akt activation at a concentration of 1μM, in HCC1937
cells subjected to insulin-like growth factor 1 (IGF-1).
Our data defined a subset of triple negative breast
cancer patients based on high activity of AKT (pS473).
This subset would be eligible for treatment using
therapies which target the PI3K/Akt pathway, such
as kinase inhibitors or phosphatase activators. In
support of this, the BRCA1 mutant cells (HCC1937)
were sensitive to the PP2a activator, FTY720. This
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suggests that FTY720 is a potential drug for use in
adjuvant therapy in breast cancer cases having a high
Akt (pS473).
Keywords Triple Negative Breast Cancer - biomarkers
- phosphatases - Akt - BRCA1.
1 Introduction
Breast cancer accounts for approximately 23% of cancer
cases in females and is responsible for 14% of cancer-
related deaths in females (Jemal et al., 2011). Classifi-
cation of breast cancers is based on morphological fea-
tures (lobular or ductal) and on the expression of the oe-
strogen receptor (ER), progesterone receptor (PgR) and
the human epidermal growth factor receptor 2 (HER2).
Breast cancer patients found negative for ER, PgR, and
HER2 (triple negative) tend to fall within the subset
of cases which have a basal-like phenotype and have a
worse overall and disease-free survival (Onitilo et al.,
2009). Interestingly, this subset has a higher occurrence
of phosphatidylinositol 3-kinase (PI3K) pathway activa-
tion (Umemura et al., 2007).
Receptor tyrosine kinases such as Her2 and insulin-
like growth factor 1 (IGF-1) receptor activate the
PI3K pathway, initiating a cascade of signals. Active
PI3K generates phosphatidylinositol 3,4,5 triphosphate
(PIP3), which serves as an anchor for Pleckstrin ho-
mology (PH)-domain containing proteins, both adap-
tor molecules such as Gab2 and Dok1 and kinases such
as Tec, Btk, PDK1 and Akt (Leevers et al., 1999;
Saito et al., 2001; Stokoe et al., 1997; Tang et al.,
1994). Activation of Akt increases cell cycle progres-
sion and maintains mammalian target of rapamycin
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(mTOR) signalling resulting in enhanced cell prolifer-
ation and survival. The PI3K pathway is attenuated by
phosphatases, including PTEN, which dephosphorylates
PIP3 (Russillo et al., 2011) and PP2A, which inactivates
mTOR effectors (Liu et al., 2010). In addition, inacti-
vation of PP2A by phosphorylation at Tyrosine 307 is
significantly correlated with HER2 positive tumour pro-
gression (Wong et al., 2010).
PI3K/Akt activates mTOR/Frap1 through phospho-
rylation of the tumour suppressor complex Tsc1/Tsc2
(tuberous sclerosis protein 1/2). Tsc1/Tsc2 releases
Rheb (Ras-homolog enriched in brain), a small GTPase
that positively modulates mTOR function (Inoki et al.,
2003). Activation of mTOR results in phosphorylation
and activation of ribosomal protein S6 Kinase (S6K;
Rps6kb1; p70S6Kinase) and hierarchical phosphoryla-
tion of 4EBP (4E-binding protein) (Wang et al., 2005).
Rapamycin-induced dephosphorylation of 4EBP is de-
pendent on the activity of protein phosphatases type
1 and 2 (Chen et al., 1998), suggesting that mTOR
inhibition releases a phosphatase to act on its down-
stream targets. Interestingly, studies on breast cancer
cell lines show an increased sensitivity of triple negative
cells to mTOR inhibitors (Noh et al., 2004). This sug-
gests that deregulation of the mTOR effectors and/or
regulators plays an important role in the pathology of
triple-negative breast cancers.
Increased Akt activation correlates with low PTEN
expression (Lopez-Knowles et al., 2010) and PI3K mu-
tations (Stemke-Hale et al., 2008). Gain of function
mutations in the PIK3CA gene (encoding the p110 cat-
alytic subunit of PI3K) are present in 25% of invasive
breast cancers (Bachman et al., 2004) and low PTEN
expression in approximately 30% of invasive breast can-
cers (Tsutsui et al., 2005).
Loss of function of the phosphatases PTEN (Marty
et al., 2008) and INPP4B (Gewinner et al., 2009) is
associated with aggressive basal-like breast carcinoma.
PTEN, INPP4B and PP2A are known antagonists of
Akt phosphorylation, hence loss of phosphatase func-
tion leads to increased Akt activation. Interestingly,
BRCA1 is known to activate PP2A, a phosphatase that
dephosphorylates Akt at Threonine 308 (T308) and Ser-
ine 473 (S473) (Ma et al., 2007; Ugi et al., 2004). This
is supported by the findings that loss of BRCA1 activity
leads to increased Akt activity (Xiang et al., 2008) and
reduced PP2A activity (Ma et al., 2007). In addition,
BRCA1 is known to bind p-Akt and lead to its ubiquiti-
nation (Chen et al., 1998). In fact one finds an enhanced
stability and higher expression of p-Akt in BRCA1 mu-
tants, in which the mutant BRCA1 lacks the ability to
bind to phosphorylated Akt (Xiang et al., 2008).
In vitro studies showed that serum starvation of
phosphatase-depleted cells maintained a high pAkt sig-
nal (Fedele et al., 2010). In this study we tested
the effect of PP2A activators on BRCA1 mutant cells
which represent a subtype of triple negative breast can-
cer patients, potentially having a suppressed PP2A
feedback mechanism. Interestingly, BRCA1 mutant
cells (HCC1937) were sensitive to the PP2A activator,
FTY720, resulting in enhanced dephosphorylation of
Akt (pS473) upon 1 hour starvation. The ER positive
cell line, MCF7, was less responsive to FTY720. In addi-
tion, restimulation of phosphorylated Akt (pS473) using
IGF-1 was blocked by FTY720. A retrospective study of
triple negative breast cancers showed a high activity of
Akt (pS473) in 27% of the cases. These cases are eligible
to pharmaceutical inhibition of the PI3K pathway and
potentially activation of the phosphatase PP2A. Acti-
vation of PP2A will allow targeting of the deregulated
PI3K pathway, including kinase mutants and cells with
a low PTEN expression, but also BRCA1 mutants due
to the sensitivity conferred by the lower PP2A activity.
2 Materials and Methods
Cell Lines Used and Culturing Conditions
Two adherent human breast cancer cell lines were used
in the study: MCF-7 and HCC1937 (ATCC). MCF-7
and HCC1937 were both cultured in sterile T-25 flasks
in an incubator with temperature set at 37◦C, having
an atmosphere of 5% CO2 and 98% humidity. The
MCF-7 cell line was cultured in high glucose Dulbecco’s
Modified Eagle’s Medium (DMEM; Sigma-Aldrich)
containing 10% Foetal Bovine Serum (FBS; Gibco,
Invitrogen) and 1% Penicillin/Streptomycin (Gibco,
Invitrogen). The HCC1937 cell line was cultured in
RPMI-1640 (Sigma-Aldrich) containing 10% FBS and
1% Pen/Strep. Passaging was carried out when the
cells reached around 90% confluence.
Dosage-Viability Experiments
The effect of different dosages of FTY720 (Cayman
Chemical) on the viability of MCF-7 and HCC1937
cells was investigated before FTY720 was used in the
experiments. MCF-7 and HCC1937 cells were seeded
in 6-well plates and allowed to reach around 90%
confluence. FTY720 was then added to each well such
that the following concentrations were obtained: 0, 0.5,
1, 2.5, and 5 μM. These were incubated overnight (for
24 hours) and the percentage of viable cells measured.
The percentage of viable cells was measured using a
CASY Cell Counter and Analyser System (Roche).
Starvation and Starvation-Stimulation Experiments
MCF-7 and HCC1937 cells were seeded in a 96-well
plate cultured for 3 days. The cells were first starved
for 2 hours by serum deprivation. After the 2 hours
elapsed, IGF-1 was added to selected wells to a final
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concentration of 200ng/mL. Cells were stimulated
for 30 or 60 minutes. FTY720 was added at a final
concentration of 1μM. At the end of the procedure,
the medium was removed from the wells by aspiration
and the cells were fixed by the addition of 3.7%
formaldehyde in 1xPhosphate Buffered Saline (PBS;
Sigma-Aldrich) and an ICW assay was performed,
using an AKt (pS473) antibody (Abcam).
Western Blotting (WB) Procedure
Western blotting was carried out on the cytoplasmic
protein fraction of MCF-7 cells in order to confirm that
the Akt (pS473) antibody to be used bound to the
intended target specifically. The cytoplasmic protein
lysate obtained from MCF-7 cells were separated
using a 7.5% SDS-PAGE (Sodium Dodecyl Sulfate
- PolyAcrylamide Gel Electrophoresis) procedure.
Electrophoresis was run for 2 hours at 150V and
30mA. The separated proteins were then transferred
using electroblotting (a semi-dry procedure) onto a
nitrocellulose membrane using a tris-glycine transfer
buffer. Blocking of the membrane was done for 1
hour at room temperature, using Odyssey blocking
buffer (LI-COR Biosciences). The primary antibody
was used at a dilution of 1 in 200 in blocking buffer
and incubation was carried out at room temperature
for 1 hour. The secondary antibody was an anti-
rabbit antibody conjugated to IRDye680 (LI-COR
Biosciences), and was used at a dilution of 1 in 15,000.
Secondary antibody incubation was carried out for 45
minutes at room temperature. The membrane was then
scanned using an Odyssey R©Infrared Imaging System
(LI-COR Biosciences), obtaining fluorescence at 700nm.
In-Cell Western (ICW) Assays
The LI-COR R©In-Cell WesternTMAssay Kit was used
in the ICW protocol. ICW assays were carried out on
MCF-7 and HCC1937 cells after the starvation and
starvation-stimulation experiments. Cells were first
fixed (20 minutes in 150μl of 3.7% formaldehyde in 1x
PBS per well) and then permeabilised (5 washes of 5
minutes each in 200μl of 0.1% Triton X-100 (Sigma-
Aldrich) in 1x PBS per well). Blocking (for 1.5 hours
with continuous shaking) was then performed using
150μl of Odyssey R©blocking buffer per well. Primary
antibody incubation was carried out using 50μl of
a 1:100 dilution of Akt (pS473) antibody per well.
Secondary antibody incubation was carried out for 1hr
on a plate shaker at room temperature. The secondary
antibody (anti-rabbit and conjugated to IRDye800)
was used at a dilution of 1:800 (50μl per well) and was
supplemented with two dyes which fluoresce at 700nm
(DRAQ5 at 1:2000 and Sapphire700 at 1:1000). The
plate was scanned using an Odyssey R©Infrared Imaging
System with detection in both 700nm and 800nm chan-
nels. The two dyes (DRAQ5 and Sapphire700) were
added in order to be able to normalise the fluorescence
obtained due to the Akt (pS473) to the number of
cells present in a given well. This is important since
variation in cell number could lead to inaccurate results.
Immunohistochemical (IHC) Staining of FFPE Tumour
Samples
A total of 47 Formalin-Fixed Paraffin-Embedded
(FFPE) triple negative breast cancer samples from
2001 to 2009 were chosen for use in the study. The
FFPE material was subjected to immunohistochemical
staining using the Vectastain Elite ABC kit (Vector
Laboratories). 3μm sections were cut from the FFPE
samples and placed on APES coated slides for IHC
staining. FFPE tissue were dewaxed using xylene and
rehdydrated in decreasing concentration of alcohol.
No antigen retrieval was necessary in the procedure
and endogenous peroxidase activity was quenched by
immersion in 3% hydrogen peroxide for 20 mins. Non-
specific binding of the primary antibody was blocked by
incubating the sections with diluted normal swine serum
(DAKO - 1/20). The primary antibody used in the pro-
cedure (1/ 40) was a rabbit polyclonal antibody raised
against Akt phosphorylated at Serine-473 (hereafter
referred to as Akt (pS473)) (Abcam), where sections
were incubated at 6◦C overnight. After washing with
PBS, the slides were incubated in diluted biotinylated
goat anti-rabbit antibody (Dako - 1/200) for 60mins
at room temperature. Following washing with PBS,
the signal produced was amplified by incubating the
sections with Avidin-Biotin Complex (ABC) containing
horse radish peroxidase (HRP) for 60mins at room
temperature. Visualisation was performed by the use
of 3,3’-diaminobenzidine (DAB), a substrate of HRP
which gives a permanent brown colour. Slides were
counterstained with haematoxylin and dehydration was
carried out in increasing concentration of alcohol. After
clearing in xylene, slides were mounted with DPX. The
stained sections were scored according to the intensity
of the stain. The score ranged from 0 to 3, with 0
being negative and 3 being intense. Samples scoring 2
or higher were considered positive for the purposes of
this study.
3 Results
In this study, BRCA1 mutant cells (HCC1937) were sen-
sitive to the PP2a activator, FTY720. Re-stimulation
of AKT (pS473) by IGF-1 was blocked by FTY720. A
subset of triple negative breast cancer patients showed
a high activity of AKT (pS473), with potential benefit
for PI3K-pathway targeted intervention.
http://dx.medra.org/10.7423/XJENZA.2014.1.08 www.xjenza.org
Phospho-Akt expression is high in a subset of Triple Negative Breast Cancer Patients 55
Figure 1: Specificity of Akt (pS473) staining and ICW analysis. A: Western Blot analysis staining using MCF-7 protein lysates stained
for Akt (pS473). Lane 1 contains the ladder while lanes 2 and 3 contain the MCF-7 protein lysates. B: Cells were seeded in 96 well
plates and stained according to the ICW protocol. Scanned image with rows A to D containing HCC1937 cells while rows E to H
contain MCF-7 cells. Columns 3, 6, 9 contain cells which have been starved for 2 hours. Columns 4, 7, 10 contain cells which have
been starved for 2 hours and stimulated for 30 minutes while columns 5, 8, 11 contain cells which have been starved then stimulated for
60 minutes. Column 2 contains the controls, A2, B2, G2, H2 being negative controls, while C2, D2, E2, F2 contain positive controls.
Columns 1 and 12 are empty.
Akt (pS473) Antibody Staining is Specific
The specificity of the Akt (pS473) antibody to be used
was first investigated by Western blotting carried out
on cytoplasmic protein lysates taken from cultured
MCF-7 cells. The Akt (pS473) antibody was expected
to bind to phosphorylated Akt at a molecular weight
of 56kDa. The bands visualised in lanes 2 and 3
are close to the band in the ladder (lane 1), which
corresponds to a molecular weight of 60kDa (Figure
1A). This confirmed that the antibody indeed binds to
the intended target and that it is quite specific since no
other bands are visible on the blot.
Cell Viability Unaffected by FTY720
FTY720 is an activator of PP2A, a phosphatase known
to inhibit Akt activity. Before performing the starva-
tion and stimulation experiments, it was necessary to
ensure that the FTY720 concentrations used in the
study do not affect the viability of these cells. MCF-7
and HCC1937 cells were incubated for 24 hours in their
respective mediums containing FTY720 at a concen-
tration ranging from 0μM to 5μM. Concentrations of
FTY720 used were 0, 0.5, 1, 2.5, and 5μM. This range
of concentrations was chosen based on the fact that
FTY720 causes significant growth inhibition of MCF-7
cells, when used in concentrations of 5μM or higher,
over a period of 48 hours (Nagaoka et al., 2008).
The percentage of viable cells was found using a cell
counter which is able to distinguish the viable cells
from the dead cells, and hence give the viability as
the percentage of cells in a suspension which are alive.
From Table 1 one can note that FTY720 does not
affect cell viability at the concentrations used since
the percentage of viable cells remained at around 90%
throughout. FTY720 was used at a concentration of
1μM in the experiments carried out.
Table 1: Percentage viability of cultured cells
when exposed to a range of FTY720 concentra-
tions over 24 hours. MCF-7 and HCC1937 cells re-
mained viable up to a concentration of 5μM FTY720.
FTY720 can be used to investigate phosphorylation
events without affecting viability.
FTY720 Percentage Viability (%)






Serum Deprivation Results in Akt (pS473) Dephospho-
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Figure 2: HCC1937 are sensitive to serum starvation and FTY720
addition. Cells were serum starved for 4 hours in the presence
(solid line) or absence (dashed line) of 1μM FTY720. Fold change
in Akt (pS473) during starvation was measured for the MCF-7 (A)
and HCC1937 (B) cell lines. Each point represents a mean taken
over three values, with the error bars representing the standard
error. C: Following 2 hours starvation, HCC1937 cells were stim-
ulated for 1 hour with 200ng/mL IGF-1 in the presence (black
bar) or absence (open bar) of 1μM FTY720. D: Schematic di-
agram showing the attenuation mechanism of the PP2A holo-
enzyme complex. BRCA1 activates PP2A activity, hence sup-
porting the sensitivity of the BRCA1-mutant HCC1937 cells to
FTY720 (which is an activator of PP2A activity).
rylation
During the starvation experiment the phosphorylated
Akt (pS473) level was suppressed in MCF-7 and
HCC1937 cells (Figure 2A, B). In order to better
analyse the observed starvation pattern, the data was
subjected to the ANOVA statistical test at a significance
level of 0.05. It was found that there is a statistical
difference between the mean values obtained in the case
of both MCF-7 (p=0.011) and HCC1937 (p=0.000),
showing that starvation significantly affected the level
of Akt (pS473). In particular, it decreases significantly
in the first hour (p=0.017 for MCF-7, and p=0.000 for
HCC1937) but any changes beyond the first hour were
not statistically significant. Dephosphorylation of Akt
in HCC1937 was stronger, indicating that the BRCA1
mutant cells are more sensitive to starvation.
The use of FTY720 at a concentration of 1μM
resulted in the same pattern: a statistically significant
decrease in Akt (pS473) occurred within the first hour
(p=0.005 for MCF-7, p=0.000 for HCC1937). FTY720
did not produce a statistically significant difference in
Akt (pS473); however, in the case of HCC1937 the level
of Akt (pS473) was slightly lower when FTY720 was
used compared to starvation in the absence of FTY720
(Figure 2B).
IGF-1 stimulation of p-Akt is suppressed by FTY720.
From the previous starvation experiment a 2 hour star-
vation time point was selected since during starvation
p-Akt decreases significantly during the first hour.
MCF-7 and HCC1937 cells were first subjected to star-
vation (2hrs) followed by stimulation with 200ng/mL
IGF-1 (a known stimulator of Akt) for 30 or 60 minutes.
FTY720 was also used at a concentration of 1μM to
investigate whether this affects the stimulation.
The effect of FTY720, on Akt activation (measured
as the level of phosphorylated Akt (pS473)) in the two
human breast cancer cell lines (MCF-7 and HCC1937)
under conditions of starvation and stimulation was
investigated. ICW assays were carried out to measure
the level in Akt (pS473) in these cells which were
either starved by serum deprivation, or stimulated
using IGF-1 following a period of starvation. The Akt
(pS473) antibody used in IHC analysis was also used
in the ICW assays. Akt (pS473) in HCC1937 increased
by a 1.4 fold change, upon IGF-1 stimulation, when
compared to the level at 2 hrs starvation. The addition
of 1μM of FTY720 abrogated Akt activation (Figure
2C). Stimulation of MCF-7, following starvation, was
marginal (fold change < 1.2) and hence the effect of
FTY720 on stimulation was not possible (data not
shown).
Akt (pS473) Activity is High in a Subset of Triple
Negative Breast Cancer Patients
Triple negative breast cancer samples were analysed
using immunohistochemistry to investigate the fraction
which is characterised by elevated Akt activation. Of
the 47 chosen triple negative FFPE samples, 2 samples
could not be adequately analysed by immunohisto-
chemistry due to insufficient amounts of tumour tissue.
The other 45 were successfully stained with the Akt
(pS473) antibody. The staining pattern obtained with
the p-Akt antibody was, as expected, cytoplasmic
and granular in appearance (Figure 3). The staining
intensity from sample to sample varied and a range of
scores were obtained from the triple negative breast
cancer samples.
Triple negative breast cancer samples having an
intensity score of 0 or 1 were considered as having a
low expression of Akt (pS473) and consist of 73% of
analysed samples. Samples having an intensity score
of 2 or 3 were considered to have a high level of Akt
(pS473). This subset accounts for 27% of stained triple
negative breast cancer samples.
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Figure 3: FFPE breast cancer patient sample sections stained with the Akt (pS473) antibody, showing different staining intensities. In
all cases magnification was by a factor of 600, and arrows point towards a region of tumour with the appropriate intensity of stain. A:
Intensity=0 (Negative); B: Intensity=1; C: Intensity=2; D: Intensity=3.
4 Discussion
This study revealed that a subset of triple negative
breast cancer samples stained high for Akt (pS473).
FTY720, a pharmacological activator of PP2A, was
shown to abrogate Akt activation by IGF-1, in the
BRCA1 mutant cell line, HCC1937.
IGF-1 Stimulation of p-Akt abrogated by FTY720
The effect of FTY720 on Akt activity in the human
breast cancer cell lines, MCF-7 and HCC1937 was
investigated. The HCC1937 cell line is negative for ER,
PgR, and HER2 and bears mutant PTEN and BRCA1
(5382insC mutation) genes. One would anticipate that
the BRCA1 mutant cells, HCC1937, have a low PP2A
activity. This is based on the studies showing that
knockdown of the BRCA1 gene leads to reduced PP2A
activity (Ma et al., 2007). In the case of MCF-7, there
is a significantly lower expression of PP2A Aα subunits
(Suzuki and Takahashi, 2003). Lowered expression of
this subunit is associated with enhanced activation of
Akt with higher expression of Akt (pS473) (Chen et al.,
2005).
MCF-7 and HCC1937 cells were subjected to star-
vation in the form of serum deprivation followed by
stimulation using IGF-1 (at 200ng/ml), both in the
presence and absence of FTY720. IGF-1 was chosen as
a stimulant since it is known to increase Akt activity by
phosphorylation at T308 and S473 (Alessi et al., 1996).
FTY720 is a pharmacological activator of PP2A, and
was used to investigate its effect on Akt activity during
serum deprivation and IGF-1 stimulation in the MCF-7
and HCC1937 cell lines. PP2A is known to inhibit Akt
activity by inhibiting phosphorylation at both T308
and S473 (Rodgers et al., 2011). Figure 2D shows
the pathway involved in the starvation-stimulation
including the action of FTY720. FTY720 was used at a
concentration of 1μM since it was shown to significantly
inhibit growth in MCF-7 cells at concentrations of 5μM
and higher (Nagaoka et al., 2008).
FTY720 at a concentration of 1μM had minimal effect
during starvation. In the case of HCC1937, a lower Akt
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(pS473) level was observed when FTY720 was added;
however, this was not statistically significant except
at 4 hours of starvation. In the case of MCF-7 there
was almost no difference in Akt (pS473) activity with
and without FTY720 during starvation. FTY720 had
a considerably more pronounced effect during IGF-1
stimulation, where it suppressed Akt (pS473) stimula-
tion in the HCC1937 cell line. Of particular interest is
the fact that the HCC1937 cell line is triple negative
and is known to have an enhanced Akt activity. This
implies that FTY720 is a potential therapeutic agent in
the treatment of triple negative breast cancer patients
having an elevated Akt activity. This is especially
important since there are few therapies which are
effective in treating triple negative breast cancers.
A Subset of Triple Negative Breast Cancers Asso-
ciated with High Akt (pS473)
To investigate the activation of Akt among triple
negative (ER, PgR, and HER2 negative) breast cancer
cases, a number of triple negative FFPE samples were
chosen and stained with the Akt (pS473) antibody.
Phosphorylation of Serine 473 and Threonine-308 are
required for full activation of Akt (Bellacose et al.,
2005). A wide range of scores were obtained (Table
2), with 16% (7/45) samples showing no staining, 58%
(26/45) showing weak staining (score 1), 22% (10/45)
showing intermediate staining (score 2), and 4% (2/45)
showing strong staining (score 3).
One could split the group of triple negatives into two
subgroups: those that had a low Akt (pS473) score
(0-1, 74%) and those that had a high Akt (pS473) score
(2-3, 26%). The subset of triple negatives having a high
activation of Akt would be eligible for therapy targeted
at the PI3K/Akt pathway. This is of great importance
since triple negative breast cancer patients derive little
benefit from current therapies.
Table 2: Distribution of Intensity scores fol-
lowing Immunohistochemistry staining with Akt
(pS473). The range of Akt (pS473) scores and the re-
spective frequency of each among triple negative breast
cancer (TNBC) FFPE samples. 45 samples were stained








This study has shown that a subset of triple negative
breast cancer (TNBC) cases in Malta, consisting of 26%
of cases, have a moderate to high activation of Akt.
Staining for phosphorylated Akt can be introduced in
the clinic to classify TNBC patients and predict the po-
tential use of targeted therapies. This subset would be
eligible for therapies targeting the PI3K/Akt pathway.
This is of great importance due to a current lack of ef-
fective therapies against triple negative breast cancer
cases. Potential therapies which target the PI3K/Akt
pathway include kinase inhibitors of mTOR and Akt,
such as Palomid529 (Xue et al., 2008), and phosphatase
activators such as FTY720 (Ugi et al., 2004). The po-
tential use of FTY720 as a therapy in breast cancer cases
having elevated levels of Akt (pS473) is supported by
the finding that at a concentration of 1μM it suppressed
stimulation of Akt activity by IGF-1 in HCC1937 cells
in vitro. Interestingly, a correlation between a high
level of Akt (pS473) and low expression of BRCA1 was
found in Breast Cancer patients (Xiang et al., 2011).
This supports our observations that breast cancer cases
bearing a mutant BRCA1 gene or reduced BRCA1 ex-
pression could also be eligible for therapy targeting the
PI3K/Akt pathway.
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